Results 41 to 50 of about 510,312 (368)

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints [PDF]

, 2011
Recent advances in cardiovascular magnetic resonance (CMR) now allow the accurate and reproducible measurement of many aspects of cardiac and vascular structure and function, with prognostic data emerging for several key imaging biomarkers.
Ashby, D, Elliott, P, Petersen, SE, Pitcher, A   +3 more
core   +2 more sources

Options for basing Dietary Reference Intakes (DRIs) on chronic disease endpoints: report from a joint US-/Canadian-sponsored working group. [PDF]

, 2016
Dietary Reference Intakes (DRIs) are used in Canada and the United States in planning and assessing diets of apparently healthy individuals and population groups.
Ard, Jamy, Atkinson, Stephanie, Bier, Dennis, Carriquiry, Alicia, Garza, Cutberto, Greene-Finestone, Linda, Harlan, William, Hattis, Dale, King, Janet, Krewski, Daniel, MacFarlane, Amanda, OConnor, Deborah, Prentice, Ross, Rodricks, Joseph, Wells, George, Yetley, Elizabeth   +15 more
core   +1 more source

Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol

BMJ Open, 2022
Introduction Using a surrogate endpoint as a substitute for a primary patient-relevant outcome enables randomised controlled trials (RCTs) to be conducted more efficiently, that is, with shorter time, smaller sample size and lower cost. However, there is
Derek Stewart, Rod Taylor, Christopher Weir, Oriana Ciani, Philippa Davies, Anthony Muchai Manyara, Valerie Wells   +6 more
doaj   +1 more source

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsResearch in context

EClinicalMedicine, 2023
Summary: Background: Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and ...
Oriana Ciani, Anthony M. Manyara, Philippa Davies, Derek Stewart, Christopher J. Weir, Amber E. Young, Jane Blazeby, Nancy J. Butcher, Sylwia Bujkiewicz, An-Wen Chan, Dalia Dawoud, Martin Offringa, Mario Ouwens, Asbjørn Hróbjartssson, Alain Amstutz, Luca Bertolaccini, Vito Domenico Bruno, Declan Devane, Christina D.C.M. Faria, Peter B. Gilbert, Ray Harris, Marissa Lassere, Lucio Marinelli, Sarah Markham, John H. Powers, Yousef Rezaei, Laura Richert, Falk Schwendicke, Larisa G. Tereshchenko, Achilles Thoma, Alparslan Turan, Andrew Worrall, Robin Christensen, Gary S. Collins, Joseph S. Ross, Rod S. Taylor   +35 more
doaj   +1 more source

true endpoint, surrogate endopoint

Journal of JCS Cardiologists, 2001
林 同文
openaire   +3 more sources

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. [PDF]

, 2013
IntroductionDuchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followed for 48 weeks in a multicenter, randomized, double-blind, placebo-controlled trial of ataluren.
Abresch, R Ted, Barth, Jay, Eagle, Michelle, Elfring, Gary, Florence, Julaine M, Gappmaier, Eduard, Glanzman, Allan M, Henricson, Erik K, McDonald, Craig M, Peltz, Stuart, PTC124-GD-007-DMD Study Group, Reha, Allen, Spiegel, Robert   +12 more
core   +2 more sources

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China

Frontiers in Public Health, 2022
ObjectiveThis study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China.Materials and methodsCancer drugs marketed before June 30th, 2021 with publicly ...
Kexin Ling, Huli Qin, Yiman Feng, Hongxi Che, Jinxi Ding, Jinxi Ding, Wei Li, Wei Li   +7 more
doaj   +1 more source

Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition

Journal of Causal Inference, 2015
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive response endpoint as a valid surrogate endpoint for a clinical endpoint, where a chief purpose of a valid surrogate is to provide a way to make correct ...
Gilbert Peter B., Gabriel Erin E., Huang Ying, Chan Ivan S.F.   +3 more
doaj   +1 more source

Debate: Are surrogate end-point studies worth the effort?

Current Controlled Trials in Cardiovascular Medicine, 2000
Surrogate end-points of cardiovascular disease can provide useful information in cross-sectional, prospective and interventional studies. They provide information on association with risk factors, natural history and factors associated with disease ...
Elkeles Robert S, Valabhji Jonathan
doaj   +1 more source

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

Cancers, 2020
Simple Summary Surrogate radiology-based endpoints such as progression-free survival (PFS) and objective response rate (ORR) are commonly used in oncology. However, their surrogacy with overall survival (OS) has not been evaluated in immunotherapy trials
G. Cabibbo, C. Celsa, M. Enea, S. Battaglia, G. Rizzo, A. Busacca, D. Matranga, M. Attanasio, M. Reig, A. Craxì, C. Cammà   +10 more
semanticscholar   +1 more source